Ghoreschi Kamran, Mrowietz Ulrich, Röcken Martin
Department of Dermatology, University of Tübingen, Liebermeisterstrasse 25, 72076 Tübingen, Germany.
J Mol Med (Berl). 2003 Aug;81(8):471-80. doi: 10.1007/s00109-003-0460-9. Epub 2003 Jul 18.
Psoriasis is an autoimmune disease affecting 2-4% of the Caucasian population. Inflammatory processes induce the migration of interferon (IFN) gamma producing Th1 lymphocytes into the skin. These play a key role in the pathogenesis of psoriasis. These Th1 lymphocytes are responsible for the pathological reactions in psoriatic skin leading to keratinocyte hyperproliferation, small vessel proliferation and neutrophilic infiltration. Antigen-presenting cells activate dermal CD4+ T lymphocytes, and various signals can support the polarization of Th1 responses. The main signal for Th1 development is interleukin (IL) 12. After binding to their receptors both IL-12 and IFN-gamma promote intracellular IFN-gamma production by activating signal transducer and activator of transcription (STAT) 4 or 1. STAT1 activation by IFN-gamma is followed by T-bet activation, a master transcription factor for Th1 lymphocytes. In experimental models of Th1-mediated autoimmune diseases immune deviation of polarized autoreactive Th1 into anti-inflammatory Th2 responses generally improves the disease. Therefore new therapeutic approaches based on immunomodulating molecules have been developed for psoriasis, a prototypical Th1-mediated autoimmune disorder. Recently IL-4, the most effective Th2-inducing cytokine, has been shown to be safe and efficient for treating psoriasis. Improvement was associated with the induction of a Th2 phenotype of skin infiltrating lymphocytes. This review summarizes the IL-4 inducing potential of various conventional and newer systemic therapies for psoriasis. Many of these were thought to be primarily immunosuppressive. A review of the literature reveals that most of them can induce IL-4 and Th2, and that Th2 induction may be an underestimated mode of action in the therapy of Th1-mediated autoimmune disease. Further studies are needed to determine the central role of IL-4 in the control of Th1-induced autoimmune disease, namely psoriasis.
银屑病是一种自身免疫性疾病,影响着2%-4%的白种人。炎症过程促使产生γ干扰素的Th1淋巴细胞迁移至皮肤。这些细胞在银屑病的发病机制中起关键作用。这些Th1淋巴细胞导致银屑病皮肤出现病理反应,包括角质形成细胞过度增殖、小血管增生和嗜中性粒细胞浸润。抗原呈递细胞激活真皮中的CD4+T淋巴细胞,多种信号可支持Th1反应的极化。Th1发育的主要信号是白细胞介素(IL)-12。IL-12和γ干扰素与它们的受体结合后,通过激活信号转导和转录激活因子(STAT)4或1来促进细胞内γ干扰素的产生。γ干扰素激活STAT1后会激活T-bet,T-bet是Th1淋巴细胞的主要转录因子。在Th1介导的自身免疫性疾病实验模型中,将极化的自身反应性Th1免疫偏离为抗炎性Th2反应通常可改善病情。因此,针对银屑病这一典型的Th1介导的自身免疫性疾病,已开发出基于免疫调节分子的新治疗方法。最近,最有效的Th2诱导细胞因子IL-4已被证明对治疗银屑病安全有效。病情改善与皮肤浸润淋巴细胞Th2表型的诱导有关。本综述总结了各种传统和新型系统性银屑病治疗方法诱导IL-4的潜力。其中许多方法曾被认为主要具有免疫抑制作用。文献综述表明,它们中的大多数均可诱导IL-4和Th2,并且Th2诱导可能是Th1介导的自身免疫性疾病治疗中一种被低估的作用方式。需要进一步研究以确定IL-4在控制Th1诱导的自身免疫性疾病即银屑病中的核心作用。